Insider Buying: Cardiol Therapeutics Inc. (TSE:CRDL) Senior Officer Buys C$19,500.00 in Stock

Cardiol Therapeutics Inc. (TSE:CRDL) Senior Officer Bernard Lim acquired 10,000 shares of Cardiol Therapeutics stock in a transaction on Tuesday, December 17th. The stock was acquired at an average cost of C$1.95 per share, for a total transaction of C$19,500.00.

Cardiol Therapeutics Price Performance

Cardiol Therapeutics stock opened at C$1.89 on Friday. The company has a debt-to-equity ratio of 1.07, a quick ratio of 6.84 and a current ratio of 2.39. The firm has a market cap of C$132.07 million, a P/E ratio of -4.30 and a beta of 0.70. The business’s fifty day moving average is C$2.39 and its two-hundred day moving average is C$2.71. Cardiol Therapeutics Inc. has a 52 week low of C$1.07 and a 52 week high of C$4.26.

About Cardiol Therapeutics

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.